The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day.
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion by then.
A week ago it was suggested that the AI/semiconductor stocks sector was oversold. The decline bottomed on Wednesday and by the close of business this past Friday the sector had rebounded nicely almost across the board.
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under consideration.
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average, in June and are now UP 13.8%, on average, YTD.
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they were down 6% last week and -21.6% YTD.
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our Clinical-Stage BioTech Drug Stocks Portfolio.
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process and this is already happening.
